• White LinkedIn Icon
  • White Twitter Icon

Toronto,

Canada

THREE PILLARS

OF TURN-KEY    MODEL

1. Internal R&D

2. Program Management

3. Business and IP Support

TURN-KEY    INTERNAL R&D

1

Expert Drug Discovery
R&D T
eams Under

One Roof

2

Design and Deploy
Highly Efficient
Screening Cascades

3

allows reaching go/no-go
decisions fastest
in the industry

Retain Execution
of First-Line Assays
In-House

Partner on fully
integrated programs
or select program needs

Guaranteed R&D execution
at top industry standard

Hit generation – 

lead validation

Compound design - validation of the mode of action

Design of screening 
cascade and assay selection

Benchmarking against mechanism – 
and clinically-relevant compounds 

Oversight of experimental 
design for outsourced studies

Ideally suited for innovative therapeutic programs allowing full customization of existing and development of new assays

Highly experienced scientific team specifically tailored for each project – all R&D performed in Canada

Direct line of communication with project lead scientists, convenient EST time zone

Real-time access to project results on the cloud, 

E-lab book and compound registration modules

The expertise of our internal scientific team spans all major areas of small molecule drug discovery and preclinical development to enable the most innovative of projects and rapidly develop the asset

See all internal

R&D capabilities 

 

COVALENT INHIBITOR

DEVELOPMENT 

From early screens for stability against biological nucleophiles to the design of washout experiments, covalent inhibitor development necessitates a non-standard set of screening conditions and a unique set of studies on the critical path to development that are not accounted for by the majority of CROs and often mislead the drug discovery project. 

 

Dalriada offers most comprehensive and expert support in this field, including
a proprietary screening cascade. 

 
 

CELL BIOLOGY

We offer a wide range of cellular and molecular biology assays to characterize phenotypic SAR and the molecular pathways affected by the drug candidates. 

Assays

  • Cell-based functional screens
     

  • Cell viability and proliferation
     

  • >70 cancer and normal cell
    lines in-house

     

  • Primary cells
     

  • Custom phenotypic assays
     

  • Immuno-assays (Western,
    ELISA)

     

  • RT-PCR
     

  • Radioligand-based assays
    (e.g. GPCR)

Instrumentation

  • Flow Cytometry
     

  • Microplate readers
     

  • HT Fluorescence
    Microscopy

     

  • Confocal Microscopy
     

  • Fluorescence-coupled thermal cyclers

Supporting projects from early discovery
to late-stage lead optimization

MEDICINAL CHEMISTRY

Medicinal Chemistry 

Target Expertise

  • Rational drug design
     

  • Computational modeling
     

  • In-silico screening
     

  • DFT calculations
     

  • Hit ID
     

  • Hit-to-Lead SAR
     

  • Lead optimization SAR
     

  • StarDrop™ QSAR analysis

  • Kinase inhibitors

  • Enzyme inhibitors

  • Targeted covalent inhibitors

 

  • Protein-protein interaction inhibitors

  • GPCR

 
 

IN VITRO ASSAY

We offer fully customizable assay development to enable the SAR efforts of your drug discovery projects and provide detailed kinetic and thermodynamic characterization for the lead compounds

  • Radioligand
    displacement assays

     

  • SPR (automated,
    microplate format)

     

  • ITC (automated,
    microplate format)

     

  • NMR binding studies
     

  • LC-MS/MS
     

  • Fluorescence-coupled
    assays

  • Fluorescence polarization
     

  • Thermal shift assays
     

  • Luminex assays
     

  • Custom assay development
     

  • Custom protein expression
     

  • Protein mutagenesis
    and labeling

     

  • Protein-ligand co-crystallization 

IN VITRO ADME

We conduct all essential in vitro ADME profiling to accelerate SAR and advance the asset

  • Microsomal & hepatocyte stability
     

  • GSH stability 
     

  • Plasma and/or whole
    blood stability

     

  • Permeability (Caco-2,
    PAMPA, MDCK)

  • CYP450 inhibition/
    induction

     

  • Metabolite ID
     

  • Proprietary Covalent
    Cascade

 

Synthesis

  • Libraries (mg)
     

  • Scale-up (g)
     

  • Peptide synthesis
     

  • Microwave-assisted synthesis
     

  • Automated chromatography
     

  • Preparative HPLC
     

  • Online inventory, barcoded

Synthesis support: 

  • Synthesis of small
    molecule libraries (mg) 
     

  • Scale-up of
    lead compound (s)

Analytical

1

13

19

  • NMR (   H,    C,     F)
     

  • Analytical HPLC
     

  • LC-MS/MS
     

  • Elemental Analysis
     

  • IR

PK, Tox, Preclinical Studies

Efficacy Studies:

  • Study design
     

  • Formulation development 
     

  • Primary patient samples
     

  • Primary and refractory tumour samples
     

  • Expertise in cancer models 
    (including heme and brain) 

In Vivo:

  • Formulation optimization
     

  • Pharmacokinetics (ip, po, iv)
     

  • Tolerability/MTD

  • PK/PD
     

  • Efficacy
     

  • Bio-distribution studies

 

INSTRUMENTATION

Liquid Scintillation Counter

Biotage Isolera Flash Chromatography

MagPix

Microcal
PEAQ-ITC

CytoFlexS FACs

Biotage Peptide Synthesizer

Analytical and preparative
HPLC units

400 MHz NMR

Microplate Readers
and Fluorescence Microscopes

Biacore T200 SPR

Biotage
Microwave Initiator

Variety of LC/MS and LC/MS/MS

 

END-TO-END

PROGRAM MANAGEMENT

The lean approach and (semi)-virtual set-up of innovative biotechs requires sourcing of diverse expertise and management of multiple outsourced contracts. 

Dalriada lightens this operational load by centralizing the project management under one umbrella.
 

Identify and Coordinate 
All Outsourcing Needs 

Manage Data
Workflow

and Storage

Source Exclusive Scientific Capabilities 

CROs –
Collaborators –
IP – Legal

Preparation and management of data rooms for due diligence

Through existing partnerships and new engagements with world-leading academic 
investigators fundamental science – preclinical – clinical

Identify and Engage Key Scientific and 

Business Expertise
for Your Project

KOLs – consultants.
Industry – academia

 

BUSINESS AND
IP SUPPORT

Dalriada keeps the business goals of the program as a top priority and supports lean (semi) virtual organizations to enable the most cost-effective R&D program and build
the highest
value for the asset.

 

We follow an “R&D-to-milestone” approach, where the R&D is designed to reach milestones and position the assets for a successful exit.

Each asset, and type of exit (investment/partnership/IND candidate), requires a unique strategy and R&D package. We assist with and facilitate every aspect of this process.

Scientific Team

trained by a top US Law Firm 

We act as a liaison between both

your patent attorney and scientific team to develop and effectively communicate the R&D exemplification required to enable the patent claims and provide the strongest IP protection to your asset(s). 

Industry positioning
and asset development
roadmap

To optimize the design of the R&D program early-on and powerfully position the asset and program in the field

Integrated
IP support

We directly assist with IP strategy development in the NCE space that is most suitable for your particular project, competition level in the field, budget, and asset exit goals 

  • Market analysis

 

  • Indications selection
     

  • Analysis of competitors’ pipelines 
     

  • Shaping target product profile (TPP) 
     

  • Engagement of appropriate KOLs
    from industry and academia 

     

  • Program positioning for potential investors and partners
     

  • Selection of the most relevant benchmark compounds (clinical and mechanism-specific benchmarks; SOC; competitor’s leads)

  • Prior art landscaping
     

  • Defining required exemplification
     

  • Preparing application drafts 
     

  • Patentability searches
     

  • Identification of white space 

  • Selection of a patent attorney
     

  • Monitoring of competitors’ activity
     

  • Informal freedom to operate
     

  • Top patent firm partners